Multiple sclerosis center marketing: cure, progression, diet and stem cell claims, infusion pages and patient stories

A multiple sclerosis center page is read by a person in their twenties or thirties who just had an MRI after a spell of blurred vision, by someone who has lived with MS for years and wants a new neurologist, by a partner who worries about the next relapse, and by a primary care office looking for a specialist. The center may be a neurology practice with an MS focus, a hospital program with an infusion suite, or a rehab and wellness service built around fatigue and walking. Readers hope to hear that MS can be stopped, and they will find clinics online that say it can. What can a center honestly say about treatment, diet and stem cells? How should infusion and therapy pages read? This guide covers what the agencies say and how to turn it into pages, ads and referral materials that stay within the rules.

Six related topics have their own guides and are not repeated here. Emergency lines across a neurology site, device wording in the FDA’s own terms and what the front desk may share with families are covered in our guide to neurology practice marketing. Coverage wording, copay coupons and drug names in ads for an infusion suite are covered in our guide to infusion center marketing. Stem cell clinics and the FDA rules behind them are covered in our guide to stem cell clinic advertising. Tremor, deep brain stimulation and center titles are covered in our guide to movement disorder clinic marketing. Study recruitment is covered in our guide to clinical trial recruitment ads. Hyperbaric oxygen offers, including the Medicare national coverage determination that lists multiple sclerosis among conditions it does not pay for, are covered in our guide to hyperbaric oxygen therapy marketing.

What NINDS, MedlinePlus and FDA say

An MS page starts with what the disease is, how it is diagnosed and what treatment can and cannot do. The sources describe it this way:

• The NINDS page Multiple Sclerosis (MS) (last reviewed December 17, 2025) calls MS an autoimmune disorder in which the immune system mistakenly attacks healthy cells, and says MS affects people differently. It says the course of MS is different for each person, which makes it difficult to predict how a person will do with the disease.
• The same NINDS page says there is no single test to diagnose MS. Doctors use a medical history, physical and neurological exams and MRI scans of the brain and spinal cord, and may add a spinal tap, evoked potential tests or eye tests.
• NINDS says there is no cure for MS, but there are treatments that can reduce the number and severity of relapses and delay the long-term progression of the disease. It says steroid treatment for an attack makes recovery faster but does not alter the long-term outcome, and that therapy for relapsing-remitting MS can delay and in certain cases prevent secondary progressive MS, but the transition can happen even with treatment.
• NINDS says that because of the risk of interactions between alternative and conventional therapies, people with MS should discuss all the therapies they are using with their doctor, especially herbal supplements, which could have harmful effects on their own or interact harmfully with other medicines. It lists the role of the gut microbiome and diet in MS as a research topic.
• The MedlinePlus page Multiple Sclerosis (last updated September 17, 2026) says there is no specific test for MS and no cure, but treatment can help manage symptoms and slow the disease. It says MS symptoms vary from person to person.
• The FDA page Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024) says regenerative medicine therapies have not been approved to treat any neurological disorder, such as multiple sclerosis.

Two points shape the marketing. First, the agencies say treatment can reduce relapses and slow or delay the disease, which is real news worth telling, but they also say there is no cure and that the disease can progress even with treatment, so no page promises that MS will stop. Second, NINDS stresses that MS differs from person to person, so one patient’s quiet decade cannot be sold as what the next reader will get.

Cure, stop and progression claims

Under 15 U.S.C. 45, deceptive acts or practices in commerce are unlawful, and 15 U.S.C. 52 prohibits false advertisements likely to induce the purchase of drugs, devices, services or cosmetics. The FTC staff Health Products Compliance Guidance says claims about the health benefits or safety of health-related products require competent and reliable scientific evidence, and that an advertiser is responsible for the claims its ads convey, including implied ones.

For MS, the line runs between what the agencies say about treatment as a class and what a center promises a reader. “Disease-modifying medicines can reduce relapses and slow MS” restates MedlinePlus. “Stop your MS” or “no more relapses” does not; NINDS describes stopping or reversing the course of MS as a goal of research, not as something current care delivers. NINDS also says the risk of misdiagnosis is a research concern, which is one more reason for a page to describe an evaluation rather than a verdict.

Phrases that need rewriting:

• “Stop MS in its tracks” or “halt your MS”. NINDS says treatment can delay long-term progression and that the transition to secondary progressive MS can happen even with treatment. Say what treatment aims to do, in the agency’s words.
• “Cure your MS” or “reverse your MS”. NINDS and MedlinePlus both say there is no cure, and NINDS lists therapies that would stop or reverse the course of MS as work in progress.
• “Our patients never relapse” or “relapse-free with our program”. This is an outcome claim that needs substantiation the center does not have, and NINDS says the course of MS is difficult to predict.
• “Repair your myelin”. NINDS lists myelin repair as a research aim. Leave it out of service pages.

Diet, supplement and wellness offers

MS readers are flooded with diet plans, supplements, detox programs and wellness packages that promise to calm the immune system. NINDS says research links sun exposure and higher vitamin D levels with a lower chance of developing MS and a less severe course, and that smoking is linked with a more aggressive course. It does not say a diet, a supplement or a vitamin dose treats MS; it lists diet and the gut microbiome as research questions and warns that herbal supplements can interact harmfully with other medicines. MedlinePlus suggests eating healthy foods and staying as active as a person comfortably can, as part of living with MS.

A center can offer nutrition counseling, quit-smoking help and exercise programs and describe them in those terms. It cannot sell them as MS treatment. Dietitian services follow our guide to dietitian marketing, wellness claims follow our guides to integrative medicine marketing claims and functional medicine practice marketing, and products sold at the front desk follow our guide to selling supplements in a medical practice.

Phrases that need rewriting:

• “The MS diet that puts you in remission”. NINDS lists diet as a research topic; offer nutrition counseling without a remission claim.
• “High-dose vitamin D protocol for MS”. NINDS describes an association in research, not a treatment. Dosing decisions belong to the treating clinician, not an ad.
• “Natural immune reset” or “detox your MS”. No source cited here supports it, and NINDS warns that supplements can interact with medicines.
• “Replace your medication with our program”. NINDS says people with MS should discuss every therapy they use with their doctor.

Stem cell and regenerative offers

Search for MS treatment and stem cell clinics appear quickly. The FDA page cited above says regenerative medicine therapies have not been approved to treat any neurological disorder, naming multiple sclerosis first. It says these unapproved products require FDA licensure or approval to be marketed and, before approval, FDA oversight in a clinical trial, and it lists safety concerns that include blindness, tumor formation, neurological events and infections. It says that a person charged for these products or offered them outside a clinical trial is likely being deceived and offered a product illegally, and that a listing on clinicaltrials.gov or an FDA registration does not mean a product is legally marketed.

An MS center should not offer these products, refer patients to clinics that do, or place ads next to them. A center that runs or refers to an FDA-overseen study describes it as research, with no promise of benefit, as our clinical trial recruitment guide linked above explains. Our stem cell guide linked above covers the FTC cases and the FDA rules in full.

Diagnosis and second opinion pages

Readers come to an MS center after a first attack, an abnormal MRI or a diagnosis they doubt. Keep the evaluation page in the agency’s terms. NINDS describes the tests that may be used, and says doctors can diagnose MS in the majority of cases by considering a person’s symptoms and identifying characteristic MS signs on an MRI. NINDS and MedlinePlus both describe a clinically isolated syndrome and a radiologically isolated syndrome, and MedlinePlus says not everyone with a clinically isolated syndrome develops MS afterward.

Phrases that need rewriting:

• “One scan tells you if you have MS”. NINDS says there is no single test to diagnose MS; describe the MRI as one part of an evaluation.
• “New blood test rules MS in or out”. NINDS describes blood and imaging biomarkers as tests NIH is still studying. Describe a test only for the use its label or the ordering lab states, and leave out tests still in study.
• “You were misdiagnosed” in an ad aimed at people already diagnosed. Offer a second opinion and describe the evaluation without suggesting a reader’s diagnosis is wrong.

Treatment and infusion pages

NINDS says the therapies the FDA has approved for MS are designed to regulate or suppress the inflammatory reactions of the disease, and MedlinePlus says disease-modifying medicines may be taken as pills, injections or infusions. NINDS also describes serious risks for certain therapies, including a potentially fatal brain infection, higher infection risk and reduced vaccine response, and says one medicine is used for people who have not responded well enough to two or more MS therapies. A treatment page that lists only benefits leaves out the half of the agency’s description that matters to a patient.

Name no drug or brand in ads, and give no doses on the page; the label and the treating neurologist set the plan. An infusion suite page describes the setting, the monitoring, who staffs the chair and how scheduling and coverage questions are handled, with the coverage and copay rules in our infusion center guide linked above. When the page names an indication, use the FDA’s wording, and keep any mention of risk next to any mention of benefit.

Phrases that need rewriting:

• “The strongest MS drug, available here”. This ranks treatments by a word the agencies do not use, and naming a drug in an ad runs into the rules in our infusion guide.
• “Twice a year and forget about MS”. It turns a dosing schedule into a promise and leaves out the monitoring NINDS describes.
• “No side effects” for any therapy. NINDS lists side effects for each class it describes.

Rehab, fatigue and symptom programs

NINDS says physical activity matters for people with MS because inactivity can contribute to worsening stiffness, weakness, pain and fatigue, that water therapy, yoga and physical therapy can help manage mild spasticity, that physical and occupational therapy can help with walking, balance and fatigue, and that daily physical activity of mild to moderate intensity can significantly reduce fatigue while people avoid excessive activity and high temperatures. It also describes treatment for vision, bladder, bowel, sexual and thinking problems. These are good programs to advertise in the agency’s terms. Therapy marketing is covered in our guides to physical therapy marketing and speech and occupational therapy marketing, and bladder care in our guide to urology practice marketing.

Readers with vision changes, numbness or fatigue need a site that works for them: readable text, high contrast, forms that save progress, and pages that work with a keyboard and a screen reader. Our guide to website accessibility covers the standards. NINDS says clinical depression is a known part of MS. A support page that touches mood gives 988, the Suicide and Crisis Lifeline, for a crisis and 911 for an emergency.

Center and clinician titles

MS programs carry titles from outside bodies: center designations from patient organizations, fellowship training and board certification. Use each title exactly as the [naming body] states it, with the years it covers, and check the listing before each campaign. One clinician’s fellowship does not make the whole practice a designated center. Training and board status follow our guide to physician bio pages and board certification, and center titles follow the same rules as in our movement disorder guide linked above.

Referrals and partners

MS centers grow through primary care offices, eye doctors who see optic neuritis, general neurologists, therapy practices and infusion partners. Under 42 U.S.C. 1320a-7b(b), the federal anti-kickback statute, it is a crime to knowingly and willfully offer, pay, solicit or receive any remuneration to induce or reward referrals of items or services payable by a federal health care program. Rules on referral fees are also set state by state. Our guide to patient and physician referrals covers the general rules.

For an MS center, keep these points:

• Do not give gifts, meals, free services or payments to referring offices, therapy practices or infusion partners in return for patients without counsel’s review.
• Support from a drug maker for an event, a nurse role or patient education goes to counsel before it appears in marketing.
• Referral materials say how to reach the team, how records and MRI images come in and how notes go back, without promising an appointment date or a result.
• Practices that see Medicaid patients follow the rules in our guide to marketing to Medicaid patients.

Privacy, pixels and ads

A visit to an MS page, an infusion booking or an intake form about numbness says something about a person’s health. Keep bookings, intake answers and page clicks out of tracking pixels and ad platform tools unless a written agreement covers them; our guide to tracking pixels on practice websites covers the setup. The Google Ads personalized advertising policy lists health among its sensitive interest categories and restricts targeting based on it. Ads can target by place and by search terms, and should not be built from a patient list or a support group roster.

Under 45 CFR 164.501, a reminder about the center’s own treatment for an individual, such as an infusion appointment or a follow-up MRI, can fall outside the definition of marketing, while a message that promotes a third party’s product generally needs a signed authorization under 45 CFR 164.508. Keep message text neutral; a text that says “MS infusion tomorrow” on a lock screen discloses a diagnosis. Ask the patient how they want to be contacted.

Patient stories

A patient who describes running again after a relapse, or the first year without one, can reassure a newly diagnosed reader. It is still one person’s experience. Under 16 CFR 255.2, an ad that shows one person’s result on a key attribute is likely to be read as what others will generally achieve, unless the advertiser has substantiation for that or clearly and conspicuously discloses what people can generally expect. “No relapses in five years” is a results claim. Pair it with the NINDS wording that MS affects people differently and that its course is difficult to predict.

Get a signed authorization under 45 CFR 164.508 where the center is a covered entity, and consent for any video that shows the person walking or using a mobility aid. NINDS says thinking and memory changes can be part of MS, so make sure the patient understands the decision, and let them review the final cut. Name no medicine in the story. Our guide to testimonials and before and after photos covers the full rules.

Illustration: two MS center pages

Illustration: a page reads “Stop MS for good. Our MS Center of Excellence pairs the strongest infusion on the market with our anti-inflammatory diet and stem cell therapy. Patients go relapse-free. One MRI tells you for sure. Book now.” It promises an outcome the agencies do not describe, claims a title no body gave it, ranks a drug, sells a diet as treatment, offers a product FDA says is not approved for any neurological disorder and overstates a test.

Illustration: a second page for the same center reads “NINDS says there is no cure for MS, but treatments can reduce the number and severity of relapses and delay long-term progression. Our team, led by [Clinician name, license], completed [fellowship name, as stated by the training program] in [year]. We review your history, exam and MRI, explain each treatment option with its benefits and risks, and run infusions in our monitored suite. Our therapists work on walking, balance and fatigue, and our dietitian offers nutrition counseling. MS is different for each person; we will tell you what we know and what we do not. Call [phone].” It uses the agency’s wording, states training exactly and describes care without a promise.

Checklist before an MS campaign goes live

• No cure, stop, halt, reverse or relapse-free claims for any medicine, infusion, diet, supplement or program.
• Agency wording for what treatment can do, with NINDS or MedlinePlus named and dated, and a line that MS differs from person to person.
• Diagnosis pages say no single test diagnoses MS and describe tests still in study as research.
• Treatment and infusion pages keep risks next to benefits, name no drug or brand in ads and give no doses.
• Diet, vitamin and supplement offers are described as nutrition or wellness services, not MS treatment.
• No stem cell or regenerative offers, referrals or ad placements; studies are described as research with no promise of benefit.
• Center, fellowship and board titles match the naming body’s current listing, with years.
• No gifts, meals or payments to referral sources, and drug maker support reviewed by counsel.
• Bookings and intake answers stay out of pixels and ad audiences; reminder text does not name MS.
• Stories have signed authorizations, name no medicine and carry a disclosure of what people can generally expect.
• Support pages give 988 for a crisis and 911 for an emergency.

How we help

We build websites, local search, Google Ads and AI front desk tools for independent practices and health businesses, including neurology, MS and infusion programs. For an MS center, that means a site that describes care in NINDS and MedlinePlus wording, keeps risks next to benefits, states titles exactly as the naming body lists them and works for readers with vision changes and fatigue, plus booking forms that keep diagnoses and symptoms off the web and away from tracking tools. We do not decide how care is delivered; your clinicians do. Our tools are built with HIPAA in mind. We confirm in writing what a BAA covers before any patient information flows through a tool, and if it is not covered, we do not route patient information through it. We are not a healthcare provider and we do not give legal or medical advice. We do not sell lead lists and we do not pay for referrals. For the wider rules, see our healthcare marketing rules hub.

Sources

• NINDS: Multiple Sclerosis (MS) (last reviewed December 17, 2025)
• MedlinePlus: Multiple Sclerosis (last updated September 17, 2026)
• FDA: Important Patient and Consumer Information About Regenerative Medicine Therapies (content current as of April 8, 2024)
• 15 U.S.C. 45: Unfair methods of competition unlawful
• 15 U.S.C. 52: Dissemination of false advertisements
• FTC: Health Products Compliance Guidance (December 2022)
• 42 U.S.C. 1320a-7b: Criminal penalties for acts involving Federal health care programs
• 45 CFR 164.501: Definitions
• 45 CFR 164.508: Uses and disclosures for which an authorization is required
• 16 CFR 255.2: Consumer endorsements
• Google Ads: Personalized advertising policy

More in Physician specialty marketing